ArticleFrontiers in pharmacology2026
Characteristics, accessibility and regional equity evaluation of pediatric medicines through National Drug Price Negotiation of China, 2017-2024.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Since its inception in 2017, China's National Drug Price Negotiation (NDPN) has served as a crucial mechanism for the strategic procurement of innovative medicines, with pediatric medicines representing a key and prioritized area. This study aims to systematically analyze the inclusion of pediatric medicines in the National Reimbursement Drug List (NRDL) through negotiation from 2017 to 2024, evaluate their current accessibility and regional equity, and provide evidence to support decision-making. Methods: Pediatric medicines were classified as either Co-use Medicines for Adults and Children (CMACs) or Child-Specific Medicines (CSMs). Descriptive statistics were used to characterize two types of pediatric medicines. Referring to the WHO/HAI calculation methodology, availability was measured by the Drug Availability Rate (DAR) and the Drug Provision Rate (DPR) of medical institutions and retail pharmacies. Affordability was assessed by Defined Daily Dose cost (DDDc), considering the proportion of China's household disposable income required to cover annual treatment costs, with a ratio of ≤1 being considered affordable. The Gini coefficient was used to calculate regional equity. Pearson's correlation test ( Results: A total of 108 pediatric medicines were identified. Among these, 83 medicines (76.85%) were CMACs and 79 (73.15%) were Child-Appropriate Formulations (CAFs). The average delay between market launch to inclusion in NRDL for pediatric medicines was 4.40 years (SD = 6.76). Regarding availability, Q1-Q2 2025 pediatric medicines demonstrated DAR of 7.89% and DPR of 8.71% in tertiary medical institutions, significantly higher than that in secondary and lower-level institutions ( Conclusion: Although China's NDPN policy has successfully improved the affordability and accelerated the inclusion of pediatric medicines, significant "last-mile" barriers persist. Critical gaps remain in the availability of CAFs and access across healthcare institutions and regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.